Cannabis
Q2 Online Sales Nearly Double Q1 Performance for Nass Valley Gateway’s Product Line
Online sales for Q2 increased from Q1 while Google Ads revenue more than doubled. Increases in conversion rates justify scaling ad spend in Q3.
Vancouver, British Columbia–(Newsfile Corp. – July 13, 2021) – Nass Valley Gateway Ltd (CSE: NVG) (CSE: NVG.CN) (OTC Pink: NSVGF) (FSE: 3NVN) (the “Company”) distributor of top quality THC-free, broad and full spectrum CBD consumables, is pleased to announce their Q2 online sales have nearly doubled from Q1. Nass Valley Gateway has made a calculated effort to establish and scale multiple sales channels, such as Google Ads. Nass Valley Gateway started 2021 with the release of its new diverse product offerings and a fresh branding overhaul.
In the last 3 months, the bounce rate — representing the percentage of website visitors who leave a website without browsing other pages — has been reduced significantly. This indicates marketing efforts are finding well-targeted audiences to stay on the website platforms and purchase products. Website users also spent more time on website platforms in Q2 compared to Q1. Every product category, including CBD oils, capsules, edibles, skincare, relief topicals, and Delta 8, have shown sales increases respectively Q/Q.
“We expected the conversion performance increase between Q1 and Q2 and project it will continue to increase as we scale our online ad spend. We are executing on our annual marketing strategy and plan. The remainder of the year should continue to show growth in every sales channel accordingly,” says Michael Semler, Nass Valley Gateway’s Chief Executive Officer.
Brandon Gil, who leads the digital agency Gil Ventures and spearheads Nass Valley Gateway’s online presence, stated, “Despite the traditional restrictions of social and search platforms, our ads have been able to continue scaling from 2020. We will continue to grow our presence in the market and achieve our annual goals.”
ABOUT NASS VALLEY GATEWAY LTD:
Nass Valley Gateway LTD (NVG) is a publicly traded company on the CSE, OTC Pink, and Frankfurt markets focused on the distribution and sales of organic, non-GMO, 3rd party lab verified CBD products for human and pet consumption. Nass Valley CBD products are sold under the “Nass Valley Gardens”, a wholly-owned subsidiary, via retail, wholesale, direct sales, and digital sales channels.
We seek Safe Harbor.
Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.
Company: Nass Valley Gateway Ltd.
422 Richards Street, Suite 170
V6B 2Z4 Vancouver
Canada
E-mail: [email protected]
Corporate Website: www.nassvalleygateway.com
Product Website: www.nassvalleyproducts.com
Investor Relations
Michael Semler.
+1 (609) 651-0032
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90051
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis1 week ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan4 days ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Cannabis3 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Curaleaf4 days ago
Curaleaf Completes Acquisition of Northern Green Canada